Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial

Niels A.D. Guchelaar, Ron H.J. Mathijssen, Maaike de Boer, Marlies L. van Bekkum, Joan B. Heijns, Birgit E.P.J. Vriens, Mandy M. van Rosmalen, Lonneke W. Kessels, Lisanne Hamming, Karin J. Beelen, Peter Nieboer, Susan M. van den Berg, Esther Oomen-de Hoop, Rhodé M. Bijlsma, Monique E.M.M. Bos

Open source

DOI: 10.1016/j.eclinm.2024.103065
Published: 2025-02
Container: eClinicalMedicine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2024.103065,
  title = {Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial},
  author = {Niels A.D. Guchelaar and Ron H.J. Mathijssen and Maaike de Boer and Marlies L. van Bekkum and Joan B. Heijns and Birgit E.P.J. Vriens and Mandy M. van Rosmalen and Lonneke W. Kessels and Lisanne Hamming and Karin J. Beelen and Peter Nieboer and Susan M. van den Berg and Esther Oomen-de Hoop and Rhodé M. Bijlsma and Monique E.M.M. Bos},
  year = {2025},
  journal = {eClinicalMedicine},
  doi = {10.1016/j.eclinm.2024.103065},
  url = {https://doi.org/10.1016/j.eclinm.2024.103065}
}

RIS

TY  - JOUR
TI  - Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial
AU  - Niels A.D. Guchelaar
AU  - Ron H.J. Mathijssen
AU  - Maaike de Boer
AU  - Marlies L. van Bekkum
AU  - Joan B. Heijns
AU  - Birgit E.P.J. Vriens
AU  - Mandy M. van Rosmalen
AU  - Lonneke W. Kessels
AU  - Lisanne Hamming
AU  - Karin J. Beelen
AU  - Peter Nieboer
AU  - Susan M. van den Berg
AU  - Esther Oomen-de Hoop
AU  - Rhodé M. Bijlsma
AU  - Monique E.M.M. Bos
PY  - 2025
JO  - eClinicalMedicine
DO  - 10.1016/j.eclinm.2024.103065
UR  - https://doi.org/10.1016/j.eclinm.2024.103065
ER  -

APA

Guchelaar, N. A., Mathijssen, R. H., Boer, M. D., Bekkum, M. L. V., Heijns, J. B., Vriens, B. E., Rosmalen, M. M. V., Kessels, L. W., Hamming, L., Beelen, K. J., Nieboer, P., Berg, S. M. V. D., Hoop, E. O., Bijlsma, R. M., & Bos, M. E. (2025). Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2024.103065

Source records

crossref · retrieved 2026-09-27T10:06:43.785Z